Volume | 10 397 |
|
|||||
Actualités | - | ||||||
Maximum Haut | 3,71 | Bas Haut |
|||||
Minimum Bas | 3,2125 |
Nom Action | Symbole Action | Marché | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Action ordinaire |
Ouverture | Plus Bas | Plus Haut | Prix de clôture | Clôture Veille |
---|---|---|---|---|
3,71 | 3,2125 | 3,71 | 3,345 | 3,7516 |
Transactions Totales | Volume échangé | VWAP | Volume Financier | Volume en moyenne | Sur 52 semaines |
---|---|---|---|---|---|
123 | 10 397 | US$ 3,39 | US$ 35 240 | - | 3,2125 - 16,11 |
Dernière Transaction | Type | Quantités échangées | Prix transaction | Devise |
---|---|---|---|---|
01:23:36 | 21 | US$ 3,25 | USD |
Bilan Comptable
Capitalisation Boursière | Actions en Circulation | Float | Chiffre d'affaires | Bénéfice/Perte | BPA | Ratio Cours sur Bénéfices |
---|---|---|---|---|---|---|
4,61M | 1,38M | - | 0 | -7,6M | -5,50 | - |
Short Interest | Dividendes Par Action | Rendement du Dividende | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
plus d’informations financières »
Actualités Action GT Biopharma
Date | Heure | Source | Titre |
---|---|---|---|
14/2/2024 | 20:46 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
01/2/2024 | 18:15 | Edgar (US Regulatory) | Form 8-K - Current report |
21/12/2023 | 21:30 | Edgar (US Regulatory) | Form 8-K - Current report |
04/12/2023 | 23:00 | Edgar (US Regulatory) | Form 8-K - Current report |
06/11/2023 | 23:25 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
06/11/2023 | 23:23 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
06/11/2023 | 23:21 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
01/11/2023 | 14:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
27/10/2023 | 23:23 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
19/9/2023 | 17:56 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
22/8/2023 | 22:55 | Edgar (US Regulatory) | Form 8-K - Current report |
16/8/2023 | 01:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
Forum Action GT Biopharma
Aucune Discussion TrouvéeAjouter une Discussion
Historiques GT Biopharma Inc
Période | Ouver. | Haut | Bas | VWAP | Moyenne Vol. Quot. | Variation | % |
---|---|---|---|---|---|---|---|
1 semaine | 3,80 | 3,88 | 3,2125 | 3,69 | 4 717 | -0,455 | -11,97% |
1 mois | 4,58 | 4,77 | 3,2125 | 4,03 | 6 931 | -1,24 | -26,97% |
3 mois | 5,538 | 6,00 | 3,2125 | 4,80 | 19 203 | -2,19 | -39,60% |
6 mois | 7,35 | 9,90 | 3,2125 | 6,88 | 86 270 | -4,01 | -54,49% |
1 an | 10,50 | 16,11 | 3,2125 | 8,62 | 227 295 | -7,16 | -68,14% |
3 ans | 345,90 | 591,993 | 3,2125 | 140,34 | 215 904 | -342,56 | -99,03% |
5 ans | 165,00 | 591,993 | 3,2125 | 154,35 | 245 191 | -161,66 | -97,97% |